Insider Trading February 26, 2026

Saba Capital Disposes of 94,153 ECAT Shares in Two Trades, Raising $1.43M

Ten-percent stakeholder trims position across February 24-25 transactions while retaining majority holdings; ECAT trades near sale prices

By Maya Rios ECAT
Saba Capital Disposes of 94,153 ECAT Shares in Two Trades, Raising $1.43M
ECAT

Saba Capital Management, L.P., a reported ten-percent owner of BlackRock ESG Capital Allocation Term Trust (ECAT), sold 94,153 shares of the trust's common stock in two transactions on February 24 and 25, 2026. The dispositions, executed at $15.09 and $15.27 per share, generated approximately $1.43 million in proceeds. After the trades, Saba Capital continues to hold 23,575,057 shares of ECAT. The trust's shares currently trade around $15.19 and carry a reported 21.81% dividend yield, with dividends increased for five consecutive years according to InvestingPro.

Key Points

  • Saba Capital sold a total of 94,153 ECAT shares in two transactions on February 24-25, 2026, generating about $1.43 million.
  • After the sales, Saba Capital still owns 23,575,057 shares of BlackRock ESG Capital Allocation Term Trust; ECAT was trading near the sale prices at $15.19.
  • The trust carries a reported dividend yield of 21.81% and has increased its dividend for five consecutive years, per InvestingPro; these facts are relevant to income-focused investors and managers in asset management and ESG investing sectors.

Overview

Saba Capital Management, L.P., identified as a ten-percent owner of BlackRock ESG Capital Allocation Term Trust (EXCHANGE:ECAT), executed two separate stock sales totaling 94,153 common shares on February 24 and 25, 2026. The combined sales produced roughly $1.43 million in proceeds, with trade prices spanning $15.09 to $15.27 per share.

Transaction details

On February 24, Saba Capital sold 34,797 shares at $15.09 per share. The following day, February 25, the firm sold an additional 59,356 shares at $15.27 per share. Those two transactions together account for the reported 94,153 shares divested by the firm across the two-day period.

Post-trade holdings and market context

Following these sales, Saba Capital Management, L.P. still holds 23,575,057 shares of BlackRock ESG Capital Allocation Term Trust. The trust's share price is currently reported at $15.19, which sits within the range of the transaction prices recorded on February 24 and 25, 2026.

Income profile cited

InvestingPro data referenced in the reporting indicates that the trust offers a 21.81% dividend yield and has increased its dividend for five consecutive years. The original report notes that InvestingPro also tracks four additional key tips for ECAT investors, though those items are not detailed here.


Contextual note

The reporting provides the sale quantities, dates, prices, aggregate proceeds, the seller's remaining share count, the prevailing market price at the time of reporting, and the trust's dividend yield and dividend-growth record as stated by InvestingPro. No explanation for the sales was provided in the transaction disclosure described.

Risks

  • The report does not provide a reason for Saba Capital's sales, leaving uncertainty about whether the transactions reflect a change in the firm's view of ECAT or other portfolio considerations - this affects investor interpretation.
  • While the trust's dividend yield and consecutive increases are reported, the article does not supply information about the sustainability or drivers of that yield, creating uncertainty for income-seeking investors evaluating ECAT.
  • The limited detail on InvestingPro's additional guidance (noted as '4 additional key tips') means readers lack the full context of those pointers and cannot assess their relevance to decision-making.

More from Insider Trading

Marvell Technology President Sells $1.1M in Stock as Shares Trade Near Yearly High Apr 6, 2026 Edward Lampert Sells $58.5 Million in Lands’ End Stock; Company Posts Q4 Shortfall, Announces $100M Buyback Program Apr 6, 2026 NeonC/NeOnc President Buys $153,398 in Stock as Company Advances Financing and Clinical Timeline Apr 6, 2026 Edwards Lifesciences Executive Executes Option Exercise, Sells 1,019 Shares Apr 6, 2026 Penumbra Director Executes $32,822 Stock Sale Amid Deal and Upbeat Quarterly Results Apr 6, 2026